7212-28-4

Usage

Uses

Used in Pharmaceutical Research:
Acetamide, 2-iodo-N-phenylis used as a building block in the production of various pharmaceutical agents and chemical intermediates. Its unique reactivity and properties contribute to the development of new drugs and organic compounds, enhancing the therapeutic potential of pharmaceutical formulations.
Used in Organic Synthesis:
In the field of organic synthesis, Acetamide, 2-iodo-N-phenylserves as a key intermediate for the synthesis of complex organic molecules. Its versatility in chemical reactions allows for the creation of a wide range of compounds with diverse applications in various industries.
Used in Chemical Intermediates Production:
Acetamide, 2-iodo-N-phenylis utilized as a chemical intermediate in the production of various compounds. Its unique structure and reactivity make it an essential component in the synthesis of specialty chemicals, contributing to the advancement of chemical research and development.

Upstream product

• 38020-81-4 2-iodoacetyl chloride 
• 62-53-3 aniline 
• 60-29-7 diethyl ether 
• 623-48-3 ethyl iodoacetae 
• 105-39-5 chloroacetic acid ethyl ester 
• 615-43-0 2-iodophenylamine 
• 75-36-5 acetyl chloride 
• 587-65-5 N-chloroacetyl-aniline 
• 75-11-6 diiodomethane 
• 103-71-9 phenyl isocyanate 
• 64-69-7 Iodoacetic acid 

Downstream Products

• 76809-67-1 C₁₅H₁₄N₂O₂ 
• 23543-26-2 bromo-acetic acid-(2,4,5-tribromo-anilide) 
• 76809-88-6 2-(hydroxyamino)-N-phenylacetamide 
• 76810-07-6 1-phenyl-2(1H)-pyrazinone 4-oxide 
• 76810-28-1 5-methyl-1-phenyl-2(1H)-pyrazinone 4-oxide 
• 76850-47-0 1-phenyl-2(1H)-pyrazinone 
• 1106762-06-4 [2-{[(4-methylphenyl)sulfonyl]imino}pyrimidin-1(2H)-yl]-N-phenylacetamide 
• 1106762-10-0 N₂-[(4-methylphenyl)sulfonyl]-N₁-phenyl-N₂-pyrimidin-2-ylglycinamide 
• 1385049-62-6 2-(3-acetamido-6-methoxy-2-oxo-2H-chromen-7-yloxy)-N-phenylacetamide 
• 1387000-03-4 2-(6-methoxy-2-oxo-2H-chromen-7-yloxy)-N-phenylacetamide 

Relevant academic research and scientific papers

Synthesis and evaluation of moxifloxacin derivatives for effects on proliferation and apoptosis of NCI-H1299 cells

Eight novel moxifloxacin (MXF) derivatives 4a-h were synthesized by functional modification of the N-5-Aza ring. Their growth inhibitory activities on human non-small lung cancer cell NCI-H1299 and A549 were evaluated by the MTT colorimetric assay. Based on the half inhibitory concentration (IC50) values, we determined that compounds 4b was the most efficacious derivative (IC50 = 2.56 ± 0.07 μM for NCI-H1299 and IC50 = 13.69 ± 0.70 μM for A549, respectively) that inhibited the proliferation of NCI-H1299 cells. Of these, Compound 4b (1 – cyclopropyl – 6 – fluoro – 8 – methoxy – 4 – oxo – 7 – ((4aS,7aS) – 1 – (2 – oxo – 2 – (p – tolylamino) ethyl) hexahydro – 1H – pyrrolo [3,4-b] pyridine – 6(2H)-yl) – 1,4 – dihydroquinoline – 3-carboxylic acid) showed good potency against the growth of NCI-H1299 cells and also selectivity on HUVEC cells (IC50 > 500 μM). The dose-response relationship of the characteristic morphological changes of NCI-H1299 cells induced by Compound 4b was confirmed by AO/EB fluorescent staining. Furthermore, Compound 4b triggered apoptosis of NCI-H1299 in a concentration-dependent manner and arrested cells in the G0/G1 phase. These data indicate that the N-(p-tolyl)propanamide functionalized N-5-Aza ring of moxifloxacin may be a promising lead compound and candidate for the development of new agents against non-small-cell lung cancer.

Synthesis method and application of 2-oxo-2-(aryl phenylamine)ethyl substituted moxifloxacin series compound

The invention discloses a synthesis method and application of a 2-oxo-2-(aryl phenylamine) ethyl substituted moxifloxacin series compound. The compound has a structural formula I, wherein R1 is hydrogen, or halogen, or nitryl, or methyl or methoxyl; R2 is

With anti-prostate cancer activity of 2 - oxo - 2 - (aryl aniline) ethyl substituted star seriation of the medicinal composition (by machine translation)

The invention discloses a with anti-prostate cancer activity of 2 - oxo - 2 - (aryl aniline) ethyl substituted star seriation of the medicinal composition, its structure is of formula I, R1 Represents hydrogen or halogen or nitro or methyl or m

Heme-thiolate sulfenylation of human cytochrome P450 4A11 functions as a redox switch for catalytic inhibition

Cytochrome P450 (P450, CYP) 4A11 is a human fatty acid ω-hydroxylase that catalyzes the oxidation of arachidonic acid to the eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE), which plays important roles in regulating blood pressure regulation. Variants of P450 4A11 have been associated with high blood pressure and resistance to anti-hypertensive drugs, and 20-HETE has both pro- and antihypertensive properties relating to increased vasoconstriction and natriuresis, respectively. These physiological activities are likely influenced by the redox environment, but the mechanisms are unclear. Here, we found that reducing agents (e.g. dithiothreitol and tris(2-carboxyethyl) phosphine) strongly enhanced the catalytic activity of P450 4A11, but not of 10 other human P450s tested. Conversely, added H2O2 attenuated P450 4A11 catalytic activity. Catalytic roles of five of the potentially eight implicated Cys residues of P450 4A11 were eliminated by site-directed mutagenesis. Using an isotope-coded dimedone/iododimedone-labeling strategy and mass spectrometry of peptides, we demonstrated that the heme-thiolate cysteine (Cys-457) is selectively sulfenylated in an H2O2 concentration-dependent manner. This sulfenylation could be reversed by reducing agents, including dithiothreitol and dithionite. Of note, we observed heme ligand cysteine sulfenylation of P450 4A11 ex vivo in kidneys and livers derived from CYP4A11 transgenic mice. We also detected sulfenylation of murine P450 4a12 and 4b1 heme peptides in kidneys. To our knowledge, reversible oxidation of the heme thiolate has not previously been observed in P450s and may have relevance for 20-HETE-mediated functions.

Design and synthesis of novel 4'-demethyl-4-deoxypodophyllotoxin derivatives as potential anticancer agents

A group of podophyllotoxin (PPT) derivatives (7a-j) were synthesized by conjugating aryloxyacetanilide moieties to the 4'-hydroxyl of 4'-demethyl-4-deoxypodophyllotoxin (DDPT), and their anticancer activity was evaluated. It was found that the most potent compound 7d inhibited the proliferation of three cancer cell lines with sub to low micromolar IC50 values. Furthermore, it was demonstrated that 7d induced cell cycle arrest in G2/M phase in MGC-803 cells, and regulated the expression of cell cycle check point proteins, such as cyclin A, cyclin B, CDK1, cdc25c, and p21. Finally, 4 mg/kg of 7d reduced the weights and volumes of HepG2 xenografts in mice. Our findings suggest that 7d might be a potential anticancer agent.

Chemical modification of lipase for rational enhancement of enantioselectivity

Chemical modifications of the I287C mutant of a Burkholderia cepacia lipase afforded various I287C-X conjugates, among which I287C-PAA bearing an N-phenylacetamide (PAA) moiety showed excellent enantioselectivity and catalytic activity for secondary alcohols. Site-directed chemical modifications are powerful tools to control enantioselective biocatalysis.

Synthesis and biological screening of some novel 2-(1H-pyrazol-1-yl)- acetamides as lidocaine analogue

2-(1H-Pyrazol-1-yl)-acetamides have been synthesized by N-alkylation of pyrazoles with 2-iodoacetanilides. The new compounds have been characterized by elemental analysis, 1H NMR, 13C NMR, IR, UV-Vis and MS spectra. Acute toxicity, l

Homologation of isocyanates with lithium carbenoids: A straightforward access to α-halomethyl- and α,α-dihalomethylamides

Treatment of widely available isocyanates with monohalolithium and dihalolithium carbenoids provides a valuable protocol for the one-pot preparation of α-halo- and α,α-dihaloacetamide derivatives. While monohalolithium carbenoids can be prepared by a smoo

Addition of lithium carbenoids to isocyanates: A direct access to synthetically useful N-substituted 2-haloacetamides

The addition of lithium carbenoids to isocyanates provides a versatile access to N-substituted 2-haloacetamides: the reaction tolerates the presence of variously functionalized substituents on the nitrogen atom, including sterically demanding ones and reactive halogens. No erosion of the enantiopurity was observed in the case of optically active isocyanates. One of the substrates prepared has been employed in Charette's type chemoselective addition of a Grignard reagent to access an α-chloroketone.

Synthesis and in vitro antitumor activity of novel scopoletin derivatives

Twenty scopoletin derivatives were developed by a systematic combinatorial chemical approach and their chemical structures were confirmed by MS, IR, 1H NMR spectra and elemental analysis. Primary screening against mammary (MCF-7 and MDA-MB 231) and colon (HT-29) carcinoma cells indicated that five compounds (8d, 8g, 8j, 11b and 11g) displayed high antitumor potencies with IC50 values below 20 μM whereas scopoletin showed IC50 values above 100 μM. Moreover, the most promising compound 11g was more active than 5-fluorouracil. These results clearly indicated that the modification of the scopoletin structure could greatly increase its antitumor activity in vitro.